Bks Advisors buys $3,498,738 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Bks Advisors scooped up 2,229 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 45,837 shares of Eli Lilly and Co which is valued at $3,498,738.Eli Lilly and Co makes up approximately 1.87% of Bks Advisors’s portfolio.

Other Hedge Funds, Including , Ftb Advisors reduced its stake in LLY by selling 1,648 shares or 7.74% in the most recent quarter. The Hedge Fund company now holds 19,655 shares of LLY which is valued at $1,500,266. Eli Lilly and Co makes up approx 0.17% of Ftb Advisors’s portfolio. Meag Munich Ergo Kapitalanlagegesellschaft Mbh sold out all of its stake in LLY during the most recent quarter. The investment firm sold 118,166 shares of LLY which is valued $8,815,184.Andra Ap-fonden reduced its stake in LLY by selling 15,200 shares or 6.09% in the most recent quarter. The Hedge Fund company now holds 234,400 shares of LLY which is valued at $17,486,240. Eli Lilly and Co makes up approx 0.47% of Andra Ap-fonden’s portfolio.Ntv Asset Management reduced its stake in LLY by selling 417 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 60,256 shares of LLY which is valued at $4,495,098. Eli Lilly and Co makes up approx 1.72% of Ntv Asset Management’s portfolio.Strategy Asset Managers reduced its stake in LLY by selling 29 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 27,758 shares of LLY which is valued at $2,096,562. Eli Lilly and Co makes up approx 0.47% of Strategy Asset Managers’s portfolio.

Eli Lilly and Co opened for trading at $75.82 and hit $77.0501 on the upside on Friday, eventually ending the session at $76.33, with a gain of 0.49% or 0.37 points. The heightened volatility saw the trading volume jump to 36,29,660 shares. Company has a market cap of $84,256 M.

On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.